64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer (SECuRE) (NCT04868604)
A Phase I/IIa Theranostic Study of 64Cu-SAR-bisPSMA and 67Cu-SAR-bisPSMA for Identification and Treatment of PSMA-expressing Metastatic Castrate Resistant Prostate Cancer
🩺 Plain-English Summary (8th-Grade Level)
The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA in participants with PSMA-expressing metastatic castrate resistant prostate cancer.
Who can join: Review the eligibility criteria below.
Location: Stanford Cancer Institute — Stanford, California
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (7 Sites)
- Stanford Cancer Institute — Stanford, California
- East Jefferson General Hospital — River Ridge, Louisiana
- BAMF Health — Grand Rapids, Michigan
- Mayo Clinic — Rochester, Minnesota
- Washington University School of Medicine at Barnes-Jewish Hospital — St Louis, Missouri
- XCancer — Omaha, Nebraska
- Weill Cornell Medicine at New York-Presbyterian — New York, New York
📞 Contact the Study Coordinator
Phone: +61 (0) 2 9209 4037
Email: clinicaltrials@claritypharmaceuticals.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Prostatic Neoplasms, Castration-Resistant
- A Study of Niraparib Combination Therapies for the Treatment of Metastatic Castration-Resistant Prostate Cancer — Tucson, Arizona
- A Study of Pasritamig With Docetaxel Versus Docetaxel in Participants With Metastatic Castration-Resistant Prostate Cancer — Chandler, Arizona
- A Study of Real-World Characteristics, Treatment Patterns, and Outcomes Among mCRPC Patients Previously Treated With an Androgen Receptor Pathway Inhibitor, Taxane-Based Chemotherapy, and Lutetium-177 Vipivotide Tetraxetan — East Hanover, New Jersey
- Study of TVB-2640 in Men With Metastatic Castration-Resistant Prostate Cancer — New York, New York
- A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer — East Hanover, New Jersey
Explore by condition: All Prostatic Neoplasms, Castration-Resistant clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.